NasdaqGS:PYXSBiotechs
Pyxis Oncology (PYXS) Cash Runway Under One Year Reinforces Bearish Funding Narratives
Pyxis Oncology (PYXS) has opened 2026 with Q1 results that keep the focus on scaling the top line while absorbing ongoing losses, with trailing 12 month revenue at about US$13.9 million and a basic EPS loss of roughly US$1.28 alongside net income losses of about US$79.6 million. Over recent quarters, the company has seen revenue move from US$0 in Q1 2025 to US$11.0 million in Q4 2025, while quarterly basic EPS losses have ranged between about US$0.29 and US$0.35 per share. For investors, that...